Rizatriptan Benzoate Tablet
Product Images NDC 0093-7472

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 0093-7472). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1

Chemical structure of Rizatriptan Benzoate showing the molecular components including a triazole ring, indole-like structure, and benzoic acid moiety.*

FDA Label Image

Image 2

A line graph showing the estimated probability of response over hours post-dose for placebo, Rizatriptan 5 mg, and Rizatriptan 10 mg. The x-axis represents hours post-dose from 0 to 2 hours. The y-axis shows estimated probability of response ranging from 0% to 90%. The graph indicates increased response probability over time with higher doses of Rizatriptan compared to placebo.*

FDA Label Image

Image 3

A line graph showing the estimated probability of remediation or rescue over 24 hours post-dose for placebo, Rizatriptan 5 mg, and Rizatriptan 10 mg. The graph compares the three treatments with time on the X-axis (hours post-dose) and probability on the Y-axis (percentage).*

FDA Label Image

Image 4

A line graph comparing the percent (with 95% confidence intervals) of Rizatriptan Benzoate Orally Disintegrating Tablets versus placebo over time, measured in hours post stage 2 dose. The y-axis represents percent (0-100) and the x-axis represents time in hours (0.5 to 2.0). The graph shows an increase over time for both groups, with Rizatriptan Benzoate consistently higher than placebo.*

FDA Label Image

Image 5

Packaging label for Rizatriptan Benzoate Tablets USP 5 mg, an oral tablet product by Teva Pharmaceuticals USA, Inc. The package contains 18 unit-dose tablets (6 blister cards of 3 tablets each). The label includes dosage information, storage instructions, manufacturer details, and a barcode. The label is primarily white with blue and black text and a space for affixing a pharmacy label.*

FDA Label Image

Image 6

Packaging label for Rizatriptan Benzoate Tablets USP 10 mg, an oral tablet by Teva Pharmaceuticals USA, Inc. The label indicates an 18 unit-dose tablet package (6 blister packs of 3 tablets each). It notes each tablet contains 14.53 mg of rizatriptan benzoate USP equivalent to 10 mg rizatriptan. The label includes storage instructions, manufacturer details, and barcode information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.